SLC5A2 and cystic fibrosis: Angiotensinogen is a precursor of angiotensin I (Ang I) and Ang II, which promote CF proliferation and activation in HF (30); therefore, improvement of cardiac dysfunction by SGLT2 shRNA treatment is consistent with this effect.